In case you missed it: November 14 to November 18


Take a look back at this week's top news stories.

Chemical hair straightening may increase uterine cancer risk

A new NIH study found women who used chemical hair straightening products to be at a higher risk for uterine cancer than women who didn’t use these products.

FDA approves IUD to prevent pregnancy for up to 8 years

The Food and Drug Administration (FDA) has approved Medicine360’s supplemental new drug application to extend the use of its levongestrel-releasing intrauterine system 52mg (LILETTA) to prevent pregnancy for up to 8 years.

A new possible solution to vaginal odor?

Alyssa Dweck, MD, discusses some recent positive data presented at the 2022 NAMS meeting regarding Clairvee (Bonafide Health) as a potential treatment for vaginal odor.

Iranian hackers emerge as cyberthreat to health care computer networks

‘Charming Kitten’ believed to be a front for Islamic Revolutionary Guard Corps, according to HHS’ cybersecurity agency.

Daré Bioscience announces grant to develop vaginal thermosetting gel for delivery of live biotherapeutics

Daré Bioscience announced yesterday that it has received a grant from the Bill & Melinda Gates Foundation of $584,986 to support its efforts related to the development of a vaginal thermosetting gel formulation for the delivery of live biotherapeutics that can be reconstituted at the point of care.

FDA grants accelerated approval to mirvetuximab soravtansine-gynx for ovarian cancer

This is the first FDA-approved ADC for platinum-resistant disease, according to ImmunoGen.

Related Videos
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit:
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit:
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit:
raanan meyer, md
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit:
Related Content
© 2024 MJH Life Sciences

All rights reserved.